Show notes
@import url('https://fonts.googleapis.com/css?family=Merriweather&display=swap');
p, li, h1, h2, h3, h4 {font-family: 'Merriweather', serif;font-size:18px; color:black;}
Samuel M. Galvagno Jr., DO, PhD, MS, FCCM, Associate Professor of Anesthesiology at the University of Maryland SOM & Associate Director, Maryland Critical Care Network at UMMC and Ross Carpenter, MD, Fellow in Cardiothoracic Anesthesia at the University of Maryland, present the weekly multi-departmental critical care fellows’ lecture on “Molecular Adsorbent Recirculating System: Life on MARS.”
Lecture Summary by Dr. Erik Manninen
Introduction
* Liver transplant is the second most common transplanted organ after kidney. <10% of global needs are met.* Molecular adsorbent recirculating system (MARS) is an artificial liver support system that was developed in 1993 in Germany and became commercially available in 1999. * It removes toxins that CRRT does not (although MARS is used in conjunction with CRRT). * MARS is used as a bridge to transplant or a bridge to recovery. It is expensive and typically involves 3 sessions at a minimum, which costs about $45,000.* Used successfully to bridge three patients to transplant that suffered heat stroke.
System Components
* The system uses three different circuits: blood, albumin and low-flux dialysis. * First, blood is dialyzed against a human serum albumin dialysate solution * Then, the albumin dialysate is regenerated in a close loop in the circuit by:* passing through a low-flux dialysis filter against a standard dialysis fluid to clear water-soluble toxins * passing through two different adsorption columns: activated charcoal to clear protein-bound substances and cholestyramine & an anion-exchange resin to clear anionic substances* For one session 100g of 25% albumin is used.
Indications
* APAP overdose with one or more: INR>2.5, tbili>3, pH<7.3, and lactate >6mmol/L.* Acute fulminant liver failure in a transplant candidate* Acute on chronic liver failure in a listed transplant candidate* Primary non-functioning post liver transplant and one or more of the following: * listed for re-transplant, * UNOS criteria for PNF* hepatic artery thrombosis* INR.2, lactate >6, and clinically deteriorating* Patients with multiple organ failure on a case to case basis
Other Considerations
* N-acetylcysteine dosing should be doubled while on MARS. Other protein bound drugs also need to have dose adjustment and should be reviewed and your clinical pharmacist can be a big help with your patient while on MARS. * Efficacy of MARS is judged on improving clinical parameters like decreasing dose of vasoactive medicines and improving mental status. * There may be a role of using MARS to speed recovery of patients with acute liver failure as well, which allows earlier hospital discharge and doesn’t tie up a potential organ, which could be transplanted to a patient who truly needs it. * While there are no precise recommendations on the effective timing of initiation of artificial liver support systems they can be helpful in select cases.
References
* Mitzner, Steffen R. “Extracorporeal liver support-albumin dialysis with the Molecular Adsorbent Recirculating System (MARS).” Annals of hepatology 10.S1 (2016): 21-28.

